Skip to main content

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.

Publication ,  Journal Article
Furman, RR; Grossbard, ML; Johnson, JL; Pecora, AL; Cassileth, PA; Jung, S-H; Peterson, BA; Nadler, LM; Freedman, A; Bayer, R-L; Bartlett, NL ...
Published in: Leuk Lymphoma
April 2011

Anti-B4-blocked ricin (anti-B4-bR) is a potent immunotoxin directed against the CD19 antigen. Previous phase I and II studies suggested a possible role for anti-B4-bR as consolidation after high-dose chemotherapy and autologous stem cell transplant. Cancer and Leukemia Group B (CALGB) 9254 is a phase III study which randomized 157 patients with B-cell lymphoma in complete remission following autologous transplant to treatment with anti-B4-bR or observation. With a median follow-up time for patients of 5.8 years, the median event-free survival for protocol treatment and observation are 2.1 and 2.9 years, respectively (p = 0.275). The median overall survival for treatment and observation are 6.1 years and not reached, respectively (p = 0.063). Therefore, no differences were found in event-free survival and overall survival between protocol treatment and observation, although there was a trend toward improved survival with observation. These data fail to support a role for anti-B4-bR as consolidative therapy after bone marrow transplant in patients with B-cell lymphoma.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

April 2011

Volume

52

Issue

4

Start / End Page

587 / 596

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Transplantation, Autologous
  • Transplantation Conditioning
  • Survival Analysis
  • Ricin
  • Middle Aged
  • Male
  • Lymphoma, B-Cell
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Furman, R. R., Grossbard, M. L., Johnson, J. L., Pecora, A. L., Cassileth, P. A., Jung, S.-H., … Eastern Cooperative Oncology Group, . (2011). A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma, 52(4), 587–596. https://doi.org/10.3109/10428194.2010.543714
Furman, Richard R., Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, et al. “A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.Leuk Lymphoma 52, no. 4 (April 2011): 587–96. https://doi.org/10.3109/10428194.2010.543714.
Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H, et al. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011 Apr;52(4):587–96.
Furman, Richard R., et al. “A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.Leuk Lymphoma, vol. 52, no. 4, Apr. 2011, pp. 587–96. Pubmed, doi:10.3109/10428194.2010.543714.
Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung S-H, Peterson BA, Nadler LM, Freedman A, Bayer R-L, Bartlett NL, Hurd DD, Cheson BD, Cancer Leukemia Group B, Eastern Cooperative Oncology Group. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254. Leuk Lymphoma. 2011 Apr;52(4):587–596.

Published In

Leuk Lymphoma

DOI

EISSN

1029-2403

Publication Date

April 2011

Volume

52

Issue

4

Start / End Page

587 / 596

Location

United States

Related Subject Headings

  • Young Adult
  • Treatment Outcome
  • Transplantation, Autologous
  • Transplantation Conditioning
  • Survival Analysis
  • Ricin
  • Middle Aged
  • Male
  • Lymphoma, B-Cell
  • Immunology